Literature DB >> 2132742

Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.

D J Brooks1, V Ibanez, G V Sawle, N Quinn, A J Lees, C J Mathias, R Bannister, C D Marsden, R S Frackowiak.   

Abstract

Using positron emission tomography (PET), we studied regional striatal 18F-dopa uptake in 16 patients with L-dopa-responsive Parkinson's disease (PD), 18 patients with multiple system atrophy, and 10 patients with progressive supranuclear palsy. Results were compared with those of 30 age-matched normal volunteers. The patients with PD showed significantly reduced mean uptake of 18F-dopa in the caudate and putamen compared to controls, but while function in the posterior part of the putamen was severely impaired (45% of normal), function in the anterior part of the putamen and in the caudate was relatively spared (62% and 84% of normal). Mean 18F-dopa uptake in the posterior putamen was depressed to similar levels in all patients. Unlike patients with PD, the patients with progressive supranuclear palsy showed equally severe impairment of mean 18F-dopa uptake in the anterior and posterior putamen. Caudate 18F-dopa uptake was also significantly lower in patients with progressive supranuclear palsy than in patients with PD, being depressed to the same level as that in the putamen. Mean 18F-dopa uptake values in the anterior putamen and caudate in patients with multiple system atrophy lay between PD and progressive supranuclear palsy levels. Locomotor disability of individual patients with PD or multiple system atrophy correlated with decline in striatal 18F-dopa uptake, but this was not the case for the patients with progressive supranuclear palsy. We conclude that patients with PD have selective nigral pathological features with relative preservation of the dopaminergic function in the anterior putamen and caudate, whereas there is progressively more extensive nigral involvement in multiple system atrophy and progressive supranuclear palsy.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2132742     DOI: 10.1002/ana.410280412

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  101 in total

1.  Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.

Authors:  J O Rinne; H Ruottinen; J Bergman; M Haaparanta; P Sonninen; O Solin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

Review 2.  Progressive supranuclear palsy (Steele-Richardson-Olszewski disease).

Authors:  H R Morris; N W Wood; A J Lees
Journal:  Postgrad Med J       Date:  1999-10       Impact factor: 2.401

Review 3.  Multiple system atrophy: pathophysiology and management.

Authors:  G K Wenning; S Braune
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.

Authors:  Catherine L Gallagher; Bradley T Christian; James E Holden; Onofre T Dejesus; Robert J Nickles; Laura Buyan-Dent; Barbara B Bendlin; Sandra J Harding; Charles K Stone; Barb Mueller; Sterling C Johnson
Journal:  Mov Disord       Date:  2011-06-02       Impact factor: 10.338

5.  Neural correlates underlying micrographia in Parkinson's disease.

Authors:  Tao Wu; Jiarong Zhang; Mark Hallett; Tao Feng; Yanan Hou; Piu Chan
Journal:  Brain       Date:  2015-11-02       Impact factor: 13.501

6.  Patterns of striatal functional connectivity differ in early and late onset Parkinson's disease.

Authors:  Yanbing Hou; Jing Yang; Chunyan Luo; Ruwei Ou; Wei Song; Wanglin Liu; Qiyong Gong; Huifang Shang
Journal:  J Neurol       Date:  2016-07-09       Impact factor: 4.849

Review 7.  Brain SPECT imaging in multiple system atrophy.

Authors:  R Cilia; G Marotta; R Benti; G Pezzoli; A Antonini
Journal:  J Neural Transm (Vienna)       Date:  2005-12       Impact factor: 3.575

Review 8.  PET: its clinical role in neurology.

Authors:  D Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-01       Impact factor: 10.154

9.  Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson's disease.

Authors:  Deniz Kahraman; Carsten Eggers; Harald Schicha; Lars Timmermann; Matthias Schmidt
Journal:  J Neurol       Date:  2011-07-13       Impact factor: 4.849

10.  Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction.

Authors:  T W Robbins; M James; A M Owen; K W Lange; A J Lees; P N Leigh; C D Marsden; N P Quinn; B A Summers
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-01       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.